Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
Total Valuation
Immix Biopharma has a market cap or net worth of $473.50M. The enterprise value is $380.65M.
Market Cap$473.50M
Enterprise Value$380.65M
Share Statistics
Immix Biopharma has 52,964,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,964,550
Owned by Insiders23.06%
Owned by Institutions22.35%
Financial Efficiency
Immix Biopharma’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -28.68%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-28.68%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-1.64M
Employee Count18
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immix Biopharma is ―. Immix Biopharma’s PEG ratio is -0.34.
PE Ratio―
PS Ratio0.00
PB Ratio1.84
Price to Fair Value1.84
Price to FCF-6.99
Price to Operating Cash Flow-14.30
PEG Ratio-0.34
Income Statement
In the last 12 months, Immix Biopharma had revenue of 0.00 and earned -29.44M in profits. Earnings per share was -0.89.
Revenue0.00
Gross Profit-364.50K
Operating Income-27.21M
Pretax Income-29.40M
Net Income-29.44M
EBITDA-26.85M
Earnings Per Share (EPS)-0.89
Cash Flow
In the last 12 months, operating cash flow was -23.93M and capital expenditures -732.92K, giving a free cash flow of -24.66M billion.
Operating Cash Flow-23.93M
Free Cash Flow-24.66M
Free Cash Flow per Share-0.47
Dividends & Yields
Immix Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.36
52-Week Price Change492.05%
50-Day Moving Average8.04
200-Day Moving Average4.51
Relative Strength Index (RSI)51.32
Average Volume (3m)797.60K
Important Dates
Immix Biopharma upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Immix Biopharma as a current ratio of 10.01, with Debt / Equity ratio of 1.14%
Current Ratio10.01
Quick Ratio10.01
Debt to Market Cap<0.01
Net Debt to EBITDA3.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immix Biopharma has paid 37.72K in taxes.
Income Tax37.72K
Effective Tax Rate>-0.01
Enterprise Valuation
Immix Biopharma EV to EBITDA ratio is -2.96, with an EV/FCF ratio of -3.23.
EV to Sales0.00
EV to EBITDA-2.96
EV to Free Cash Flow-3.23
EV to Operating Cash Flow-3.32
Balance Sheet
Immix Biopharma has $100.41M in cash and marketable securities with $1.07M in debt, giving a net cash position of $99.34M billion.
Cash & Marketable Securities$100.41M
Total Debt$1.07M
Net Cash$99.34M
Net Cash Per Share$1.88
Tangible Book Value Per Share$2.85
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immix Biopharma is $18.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.25
Price Target Upside104.14% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―